Opinion|Videos|January 29, 2025
Balancing Treatment Benefits and Toxicity: Managing Quality of Life in EGFR+ NSCLC Patients
Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, highlighting strategies to address quality-of-life impacts while maintaining the benefits of treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What has been your experience in managing skin-related side effects, such as rash, in patients on EGFR inhibitors?
- How do you address the impact of skin toxicity on quality of life versus the benefit of continuing treatment?
Advertisement
Related to this article
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
The FDA has approved oral iberdomide (Zenbexus) for relapsed/refractory multiple myeloma, offering patients a highly potent, accessible therapy.
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
With daraxonrasib approved for metastatic pancreatic cancer, Yolanda Justal, APRN, discusses essential nursing workflows for home-based care.
Beth Sandy, CRNP, of Penn Medicine explains how oncology nurses and pharmacists collaborate to manage financial toxicity and secure oral therapies.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves sNDA for Taletrectinib in ROS1+ NSCLC
2
Oncology Experts Discuss On-Body Subcutaneous Isatuximab in Multiple Myeloma
3
Prostate Cancer Care: ADT Management and APP Guidance
4
Why Using AI to Interpret Mammogram Results Can Cause Unnecessary Panic
5